

Airway CD8+CD161++TCR α 7.2+ T cell depletion during Untreated HIV infection Targets CD103-expressing cells

Leonard Mvaya¹, Andrew Mwale¹, Annemarie Hummel¹, Joseph Phiri¹, Raphael kamng'ona¹, David T. Mzinza¹, Elizabeth Chimbayo¹, Rose Malamba¹, Anstead Kankwatira¹, Henry C. Mwandumba^{1,2}, Kondwani C. Jambo^{2,1*}

¹Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Malawi, ²Liverpool School of Tropical Medicine, United Kingdom

Submitted to Journal:
Frontiers in Immunology

Specialty Section:
Mucosal Immunity

Article type:
Original Research Article

Manuscript ID:
472895

Received on:
17 May 2019

Revised on:
05 Aug 2019

Frontiers website link:
www.frontiersin.org

In review

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Author contribution statement

Conception and design: KCJ, HCM, LM, AM; Analysis and interpretation: KCJ, HCM, LM, AM, AH, JP, RK, DM, EC, AMK, RDM; Drafting the manuscript for important intellectual content: KCJ, LM, HCM; Final approval: KCJ, HCM, MG, LM, AM, RK, JP, DM, AH, EC, RDM, AMK

Keywords

airway, HIV, CD103, CD8 T cell, Adult

Abstract

Word count: 205

HIV-infected adults are at an increased risk to lower respiratory tract infections. CD8+CD161++TCRalpha7.2+ T cells are an innate-like T cell subset that are thought to play an important role in early defence against pathogens in the respiratory tract. HIV infection leads to irreversible depletion of these cells in peripheral blood, however, its impact on this subset in the human airway is still unclear. Here, we show presence of CD103-expressing CD8+CD161++TCRalpha7.2+ T cells in the airway that exhibited a distinct cytokine functional profile compared to their CD103- airway counterparts and those from peripheral blood. These CD103-expressing airway CD8+CD161++TCRalpha7.2+ T cells were selectively depleted in untreated HIV-infected adults compared to healthy controls. Their frequency was positively correlated with frequency of airway CD4+ T cells. Furthermore, the frequency of airway CD8+CD161++TCRalpha7.2+ T cells was also positively correlated with HIV plasma viral load, while suppressive antiretroviral therapy (ART) resulted in restoration of airway CD8+CD161++TCRalpha7.2+ T cells. Our findings show that CD103-expressing airway CD8+CD161++TCRalpha7.2+ T cells are functionally distinct and are preferentially depleted during untreated chronic HIV infection. Depletion of CD103-expressing airway CD8+CD161++TCRalpha7.2+ T cells, at a major portal of pathogen entry, could partly contribute to the increased propensity for opportunistic lower respiratory tract infections observed in untreated HIV-infected adults.

Contribution to the field

CD8+CD161++TCRalpha7.2+ T cells are a group of innate-like T cells that play an important role in early defence against bacterial and fungal pathogens. Chronic HIV infection is associated with depletion of this important subset in peripheral blood and increased propensity for opportunistic respiratory infections. However, the impact of HIV infection on this important cell subset in the lung, a major site of HIV-mediated opportunistic infections, is still unclear. We report the presence of CD103-expressing airway CD8+CD161++TCRalpha7.2+ T cells with distinct cytokine functional profile, which are selectively depleted in untreated chronic HIV infection. The depletion of these CD103-expressing airway CD8+CD161++TCRalpha7.2+ T cells is inversely correlated with HIV plasma viral load, restored by suppressive antiretroviral therapy and positively correlated with frequency of airway CD4+ T cells. Drawing on previous findings from us and others showing impaired CD4+ T cell and alveolar macrophage responses in the lung during chronic HIV infection, findings of the present study highlight the broad impact of HIV infection on pulmonary immune responses in humans. Consequently, HIV-mediated selective depletion of CD103-expressing airway CD8+CD161++TCRalpha7.2+ T cells could partly contribute to the increased propensity for opportunistic bacterial and fungal respiratory infections observed in untreated HIV-infected adults.

Funding statement

This work was funded by the Wellcome (UK) through an Intermediate Fellowship number 105831/Z/14/Z awarded to KCJ. HCM is supported by the MRC (UK) and the Bill and Melinda Gates Foundation through grant numbers MR/P02056/1 and OPP1125279 respectively. The Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) is supported by a strategic award from the Wellcome.

Ethics statements

Studies involving animal subjects

Generated Statement: No animal studies are presented in this manuscript.

Studies involving human subjects

Generated Statement: The studies involving human participants were reviewed and approved by College of Medicine Research Ethics Committee (COMREC; protocol P.03/16/1907) and Liverpool School of Tropical Medicine Research Ethics Committee (LSTM REC; protocol 15.054). . The patients/participants provided their written informed consent to participate in this study.

Inclusion of identifiable human data

Generated Statement: No potentially identifiable human images or data is presented in this study.

In review

Data availability statement

Generated Statement: The datasets generated for this study are available on request to the corresponding author.

In review

1 **Airway CD8⁺CD161⁺⁺TCR α 7.2⁺ T cell depletion during Untreated HIV infection**
2 **Targets CD103-expressing cells**

3 Leonard Mvaya¹, Andrew Mwale¹, Annemarie Hummel¹, Joseph Phiri¹, Raphael
4 Kamng'ona¹, David Mzinza^{1,2}, Elizabeth Chimbayo¹, Rose Malamba¹, Anstead
5 Kankwatira¹, Henry C Mwandumba^{1,2}, *Kondwani C Jambo^{1,2}

6
7 ¹Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of
8 Malawi College of Medicine, Blantyre, Malawi; ²Department of Clinical Sciences,
9 Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

10
11
12
13
14 **Corresponding author:** Kondwani C Jambo, Malawi-Liverpool-Wellcome Trust
15 Clinical Research Programme, P.O. Box 30096, Blantyre 3, Malawi.
16 Tel: +265 1876444 Fax: +265 1875774
17 Email: Kondwani.Jambo@lstmed.ac.uk or kjambo@mlw.mw

18
19
20
21
22
23
24 **Running Head:** HIV-mediated selective depletion of airway
25 CD103⁺CD8⁺CD161⁺⁺TCR α 7.2⁺ T cells

26
27
28
29
30
31
32 **Total word count:** 3570 words

51 **Abstract**

52 HIV-infected adults are at an increased risk to lower respiratory tract infections.
53 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells are an innate-like T cell subset that are thought to
54 play an important role in early defence against pathogens in the respiratory tract. HIV
55 infection leads to irreversible depletion of these cells in peripheral blood, however, its
56 impact on this subset in the human airway is still unclear. Here, we show presence of
57 CD103-expressing CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in the airway that exhibited a
58 distinct cytokine functional profile compared to their CD103⁻ airway counterparts and
59 those from peripheral blood. These CD103-expressing airway
60 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells were selectively depleted in untreated HIV-infected
61 adults compared to healthy controls. Their frequency was positively correlated with
62 frequency of airway CD4⁺ T cells. Furthermore, the frequency of airway
63 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells was also positively correlated with HIV plasma viral
64 load, while suppressive antiretroviral therapy (ART) resulted in restoration of airway
65 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells. Our findings show that CD103-expressing airway
66 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells are functionally distinct and are preferentially
67 depleted during untreated asymptomatic HIV infection. Depletion of CD103-
68 expressing airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells, at a major portal of pathogen
69 entry, could partly contribute to the increased propensity for opportunistic lower
70 respiratory tract infections observed in untreated HIV-infected adults.

71
72 **Word count:** 205 words

73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

101 **Introduction**

102 HIV-infected individuals are at an increased risk to lower respiratory tract infections
103 (LRTIs)^{1,2}, which account for 75-98% of lung complications in untreated HIV-
104 infected adults worldwide^{3,4}. This susceptibility to LRTIs is largely attributed to HIV-
105 induced disruption of lung immunity, including global alteration in airway immune cell
106 homeostasis⁵, reduced frequency of respiratory antigen-specific airway CD4⁺ T
107 cells^{6,7}, as well as, impaired alveolar macrophage function^{6,8}. While these immune
108 cell perturbations partly underlie propensity for LRTIs in HIV-infected individuals, the
109 impact of HIV infection on other important cells involved in early defence^{9,10}, such
110 as airway CD161⁺⁺TCR α 7.2⁺ T cells, is not well defined.

111
112 CD161⁺⁺TCR α 7.2⁺ are classical markers for Mucosal-Associated Invariant T (MAIT)
113 cells, which are innate-like T cells present in the liver, blood and mucosal tissues
114 including gut, female genital tract (FGT) and the lung¹¹⁻¹⁴. CD161⁺⁺TCR α 7.2⁺ T
115 cells have characteristics of innate cells and a degree of sophistication possessed by
116 adaptive lymphocytes. They express a semi-invariant T cell receptor, which
117 recognises microbial vitamin B2 (riboflavin) metabolites (5-(2-oxoethylideneamino)-6-
118 D-ribitylaminoouracil or 5-OP-RU), presented via major histocompatibility complex
119 (MHC) class I-related (MR) 1 molecule¹⁴⁻¹⁷. CD161⁺⁺TCR α 7.2⁺ T cells are present
120 in three main subsets, CD4⁻CD8⁻ (DN), CD4⁺ and CD8⁺ phenotypes^{18,19}. The
121 majority of the CD161⁺⁺TCR α 7.2⁺ T cells in peripheral blood are actually of the
122 CD8⁺ phenotype¹⁸. Mature CD161⁺⁺TCR α 7.2⁺ T cells display an effector memory
123 phenotype²⁰, are pre-armed with pro-inflammatory and cytolytic effector molecules
124^{12,21}. This allows them to either lyse infected cells or activate phagocytes very early
125 after infection^{22,23}. Furthermore, CD161⁺⁺TCR α 7.2⁺ T cells contribute to regulation
126 of mucosal barrier integrity by secreting IL-22, which promotes epithelial cell
127 proliferation and epithelial tight junction protein expression^{24,25}. These qualities
128 highlight the importance of CD161⁺⁺TCR α 7.2⁺ T cells in antimicrobial defence and
129 preservation of mucosal barrier integrity.

130
131 CD161⁺⁺TCR α 7.2⁺ T cells in the human lower respiratory tract (LRT) are thought to
132 play an important role in defence against respiratory pathogens. *Streptococcus*
133 *pneumoniae* and *Mycobacterium tuberculosis* both induce CD161⁺⁺TCR α ⁺ T cell
134 responses through MR1-dependent pathways^{16,26}. In patients with active pulmonary
135 TB, CD161⁺⁺TCR α 7.2⁺ T cells are enriched in the lung¹⁶ and decreased in blood^{16,}
136^{27,28}. It has been shown that decrease in MAIT cells frequencies is linked to
137 expression of PD-1 on MAIT cells during HIV and chronic hepatitis C virus (HCV)
138 HCV infection^{29,30}. It was suggested that this expression of PD-1 potentially induces
139 inhibition of MAIT cell proliferation and function due to immune exhaustion³¹. In an
140 experimental murine *M. tuberculosis* infection, mice over-expressing
141 CD161⁺⁺TCR α 7.2⁺ T cells have lower bacilli load compared to MR1 knockout (KO)
142 mice³². This effect of CD161⁺⁺TCR α 7.2⁺ T cells in the lung happens early in
143 infection. In a *M. bovis* pulmonary infection model, higher bacterial burdens are only
144 observed at day 10 in MR1 KO mice compared to wild type mice³³, but not at day
145 30, suggesting that the impact of CD161⁺⁺TCR α 7.2⁺ T cells in controlling bacterial
146 load is much more significant in early than later stages of infection. An intranasal
147 infection of *Francisella tularensis* live-vaccine strain (LVS) in wild-type and MR1 KO
148 mice, has also established that CD161⁺⁺TCR α 7.2⁺ T cells have a direct early
149 antibacterial effect in the lung and a sustained impact on development of effective

150 adaptive mucosal immune response¹⁰. Taken together these findings suggest that
151 CD161⁺⁺TCRv α 7.2⁺ T cells in the mucosal surface of the LRT are poised to provide
152 early control of infection and mediate development of subsequent optimal adaptive
153 immune responses.

154

155 HIV infection leads to depletion of peripheral blood CD161⁺⁺TCRv α ⁺ T cells^{34, 35},
156 which is not reversed by anti-retroviral therapy (ART)³⁶. However, there are
157 conflicting data on the impact of HIV on the functional capacity of
158 CD161⁺⁺TCRv α 7.2⁺ T cells^{37, 38}. CD161⁺⁺TCRv α 7.2⁺ T cells obtained from untreated
159 HIV-infected individuals were shown to retain their ability to produce IFN- γ and TNF
160 upon stimulation with purified MR1 ligand³⁷. In contrast, following bacterial (*E. coli*)
161 stimulation, CD161⁺⁺TCRv α ⁺ T cells from untreated HIV-infected individuals were
162 shown to produce lower levels of IFN- γ , TNF and IL-17 compared to healthy controls
163³⁸. Nevertheless, disruption of this important T cell subset likely contributes to
164 increased susceptibility to infection in HIV-infected adults.

165

166 Despite important recent advances in CD161⁺⁺TCRv α 7.2⁺ T cell biology, the
167 phenotype and functional characteristics of human airway CD161⁺⁺TCRv α 7.2⁺ T
168 cells in health and asymptomatic HIV infection are not well defined. Accumulating
169 evidence suggests that CD161⁺⁺TCRv α 7.2⁺ T cells in mucosal sites may differ from
170 those in circulation^{12, 13, 39}. To address this knowledge gap, we examined the
171 frequency, phenotype and functional capacity of human airway CD161⁺⁺TCRv α 7.2⁺
172 T cells in healthy controls and asymptomatic HIV-infected adults before and one year
173 after initiation of ART.

174

175

176 **Materials and Methods**

177 **Study participants**

178 We recruited 80 individuals, classified as HIV-uninfected (n = 39), untreated
179 asymptomatic HIV-infected (n = 41) and HIV-infected on ART (n = 6) at Queen
180 Elizabeth Central Hospital, in Blantyre, Malawi. Participants were recruited from the
181 hospital's Voluntary Counselling and Testing (VCT) clinic and they were all of black
182 African origin. They were asymptomatic adults (≥ 18 yrs) with no clinical evidence of
183 active disease, willing to undergo bronchoscopy and BAL for research purposes.
184 Exclusion criteria for the study were current smoker, use of immunosuppressive
185 drugs including ART at recruitment, and known or suspected pregnancy as screened
186 by the study clinical team. Untreated HIV-infected individuals were commenced on
187 ART in line with the "test and treat" strategy soon after undergoing bronchoscopy
188 (within 36hrs post HIV diagnosis). Participant demographics including age, sex, CD4
189 count and plasma viral load are summarised in Table 1. All enrolled participants
190 gave written informed consent as per protocol approved by College of Medicine
191 Research Ethics Committee (COMREC; protocol P.03/16/1907) and Liverpool
192 School of Tropical Medicine Research Ethics Committee (LSTM REC; protocol
193 15.054). Due to limitation in cell numbers, not all experiments were done on all
194 samples. Specifically, the frequency of CD161⁺⁺TCRv α 7.2⁺ T cell data was
195 generated on all 80 samples, the CD103 containing panel was used to generate data
196 on a subset of 40 samples and the cytokine functional profile data was generated on
197 a subset of 22 samples. Furthermore, for this study, we only had access to paired
198 BAL and peripheral blood samples from HIV-uninfected individuals.

199

200 **Sample collection and experimental procedures**

201 Bronchoscopy and bronchoalveolar lavage (BAL) were performed on all participants
202 as previously described⁵. Paired peripheral blood was also obtained from study
203 participants for CD4 count and peripheral blood mononuclear cell (PBMC) isolation
204 using density gradient centrifugation. Cell counts in BAL cells and PBMCs isolated
205 from each sample were performed using a hemocytometer.

206

207 **Flow cytometry**

208 Immunophenotyping was performed as previously described⁴⁰. The antibodies used
209 are described in Supplementary Table 2. BAL cells and PBMCs stimulations were
210 performed using PMA/Ionomycin (Sigma Aldrich, UK) as a stimulant. Briefly, cells
211 were incubated at a concentration of 1×10^6 cells/200 μ l in complete medium (200 μ l
212 per condition) in the presence of PMA/Ionomycin, BD GolgiPlug (BD Biosciences,
213 UK) and BD GolgiStop (BD Biosciences, UK) for a total of 6hrs at 37⁰C in a 5% CO₂
214 incubator. After stimulation, cells were harvested and washed in PBS. Cells were
215 labeled with the amine reactive dye LIVE/DEAD Fixable Aqua (Molecular Probes,
216 Invitrogen, UK) prior to incubation with antibodies against surface proteins.
217 Cytokines were stained after subsequent fixation/permeabilization with BD
218 Cytotfix/Cytoperm (BD Biosciences, UK).

219

220 **Cytometric Analyses**

221 For all flow cytometric assays, at least 5,000 events in the CD8⁺ T cell gate were
222 acquired using a LSRFortessa equipped with FACSDIVA software (BD Biosciences).
223 Data were analyzed with FlowJo software (version 10.4.0, Tree Star). For cytokine
224 functional profiles, PESTLE 1.7 and SPICE 5.3 (both NIAID, USA) were used for
225 analysis. The programs PESTLE and SPICE were kindly provided by Mario
226 Roederer, Vaccine Research Center, NIAID, NIH.

227

228 **Statistical analysis**

229 Statistical analyses and graphical presentation were performed using GraphPad
230 Prism 5 (GraphPad Software, USA). Non-parametric tests were used to determine
231 significance between groups using the Mann-Whitney two-tailed test (for two groups)
232 or the Wilcoxon matched-pairs two-tailed test (for paired samples) (*p < 0.05; **p <
233 0.01; ***p < 0.001). Pearson test was used to measured association between
234 parameters.

235

236

237 **Results**

238 **CD8⁺CD161⁺⁺TCR α 7.2⁺ T cells are present at similar frequencies in the airway 239 lumen and systemic circulation**

240 To determine frequency of CD8⁺CD161⁺⁺TCR α 7.2⁺ T cells from the airway lumen
241 and systemic circulation, we obtained BAL fluid and peripheral blood from healthy
242 HIV-uninfected adults, respectively (Table 1). Using flow cytometric analysis (Figure
243 1A and Supplementary Figure 1), we found similar frequencies of
244 CD8⁺CD161⁺⁺TCR α 7.2⁺ T cells in airway and peripheral blood samples (Figure
245 1B). As expected, the majority of CD8⁺CD161⁺⁺TCR α 7.2⁺ T cells from both airways
246 and blood exhibited a memory phenotype (CD45RO⁺) (94% [75-100] vs. 84% [76-
247 90], p=0.4867) (Figure 1C). CD8⁺CD161⁺⁺TCR α 7.2⁺ T cells were predominantly
248 MR1 5-OP-RU positive (70%) and were the most abundant MR1 5-OP-RU positive

249 population (Supplementary Figure 2 and 3). However, due to low event numbers in
250 the airway CD8⁺CD4⁻(DN) CD161⁺⁺TCRvα7.2⁺ T cell population, we have only
251 focused on the CD8⁺CD161⁺⁺TCRvα7.2⁺ T cell population in this manuscript. These
252 results confirm the presence of mature CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in the
253 airway of Malawian HIV-uninfected adults.

254

255 **CD103-expressing CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells are the predominantly** 256 **located in the airway lumen compared to systemic circulation**

257 We then further characterised the phenotype of the CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells
258 by measuring CD103, a mucosal retention receptor commonly used to differentiate
259 tissue-resident from infiltrating cells. CD103 is required for retention of cells in
260 tissues as it binds to epithelial cell-expressed E-cadherin^{41, 42}. The proportion of
261 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells expressing CD103 was higher in airway compared
262 to blood (77% [46-89] vs. 2% [0.32-2.6], p<0.0001) (Figure 2A and 2B). Furthermore,
263 airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells expressed higher levels of CD103
264 compared to airway classical CD8⁺ T cells (Figure 2C). These results show that
265 airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells are predominantly resident cells, but also
266 contains a subset of potentially circulating/non-resident cells.

267

268 **CD103-expressing airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells possess a distinct** 269 **cytokine functional profile**

270 Next, we tested whether CD103-expressing airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells
271 were functionally distinct from CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in peripheral blood
272 (Supplementary Figure 4). The cytokine functional profile was different between
273 airway and blood CD8⁺CD161⁺⁺TCRvα⁺ T cells (Figure 3A). Specifically, a greater
274 proportion of airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells were bi-functional compared to
275 those from blood (BAL CD103⁺ 60% vs. Blood CD103⁻ 30%, p<0.0001; BAL CD103⁻
276 65% vs. Blood CD103⁻ 30%, p=0.0018). Furthermore, the frequency of IFN-γ & TNF
277 & IL-17A triple-producers, TNF & IL-17A duo-producers, IL-17A single-producers,
278 and IFN-γ single-producers were higher in airway CD103⁺CD8⁺CD161⁺⁺TCRvα7.2⁺
279 T cells than peripheral blood CD103⁻CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells (p<0.01,
280 p<0.05, p<0.01 and p<0.05, respectively; Figure 3A). On the other hand, the
281 frequency of TNF single-producers were higher in peripheral blood CD103⁻
282 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells than in CD103-expressing airway
283 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells (p<0.01; Figure 3A).

284

285 We then investigated whether there was a functional difference between CD103-
286 expressing CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells compared to non CD103-expressing
287 cells from the airway lumen. The frequency of TNF and IL-17A duo-producers was
288 higher in CD103-expressing than in non CD103-expressing cells (p<0.01; Figure
289 3A). Furthermore, the frequency of CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells and classical
290 CD8⁺ T cells from the airways producing IL-17A was higher in CD103-expressing
291 compared to non CD103-expressing cells (Figure 3B), but this was not the case with
292 IFN-γ or TNF (Supplementary Figure 5). Collectively, the results indicate that CD103-
293 expressing airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells are functionally distinct, and that
294 CD103 expression is associated with a propensity for IL-17A-production in airway
295 CD8⁺ T cells.

296

297 **Selective depletion of airway CD103-expressing CD8⁺CD161⁺⁺TCRvα7.2⁺ T**
298 **cells in untreated HIV-infected adults**

299 HIV is associated with a depletion of peripheral blood CD161⁺⁺TCRvα7.2⁺ T cells³⁴,
300³⁵, we investigated whether asymptomatic HIV infection alters the frequency of
301 airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells. The frequency of airway
302 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells was significantly lower in untreated HIV-infected
303 individuals compared to healthy controls (Figure 4A and 4B). In a subset of
304 individuals, with paired CD8⁺ and DN CD161⁺⁺TCRvα7.2⁺ T cells, we found no
305 difference in this population between HIV-infected adults compared to healthy
306 controls (Supplementary Figure 3). Specifically, the frequency of CD103-expressing
307 airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells was lower in untreated HIV-infected adults
308 than in HIV-uninfected controls, but the frequency of non CD103-expressing airway
309 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells was similar between the two groups (Figure 4C). In
310 contrast, the frequency of total CD8⁺ T cell was higher in untreated HIV-infected
311 adults than in HIV-uninfected controls (Figure 4D).

312
313 Furthermore, there was reduction in the distribution of CD103-expressing airway
314 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in untreated HIV-infected adults compared to HIV-
315 uninfected adults (52% vs. 78%, p<0.001) (Figure 4E). We also found that the
316 frequency of CD103-expressing airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells was
317 positively correlated with the frequency of airway CD4⁺ T cells (p=0.0273, r=0.3490;
318 Figure 4F). Collectively, these findings show that depletion of airway
319 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in untreated HIV-infected adults targets the CD103-
320 expressing cells.

321
322 **HIV viral burden is associated with the frequency of airway**
323 **CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells**

324 HIV has direct pro-apoptotic impact on diverse cell types⁴³. We therefore
325 determined whether the depletion of airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells is
326 associated with HIV viral burden. We measured the association between HIV plasma
327 viral load or peripheral blood CD4 count with frequency of airway
328 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in 25 untreated HIV-infected adults with complete
329 data. We found that HIV plasma viral load was inversely correlated with the
330 frequency of airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells (Figure 5A). In contrast, the
331 frequency of airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells was not directly correlated with
332 peripheral blood CD4 count (Figure 5B).

333
334 To ascertain the impact of HIV viral burden on the depletion of airway
335 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells, we investigated whether suppressive antiretroviral
336 therapy (ART) leads to recovery of airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells. We
337 utilised 6 HIV-infected adults to which we had paired baseline CD8⁺CD161⁺⁺TCRvα⁺
338 T cell data before commencement of ART and one year post ART initiation. All
339 individuals had undetectable HIV plasma viral load at one year post ART initiation.
340 Representative plots from an HIV-infected participant, before and one year following
341 ART initiation (Figure 5C). Despite, having a small sample size, the frequency of
342 airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells increased one year following initiation of
343 ART (Figure 5D). Collectively, the findings show that HIV could directly or indirectly
344 drive depletion of airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells and that ART leads to
345 reconstitution of these cells.

346

347 **The cytokine-functional profile of airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells is**
348 **minimally impacted by HIV infection**

349 Lastly, we investigated whether HIV infection alters cytokine functional profile of
350 airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells. Overall, the cytokine-producing functional
351 profile in airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells was not different between
352 untreated HIV-infected adults compared to HIV-uninfected individuals, in both the
353 CD103⁺ and CD103⁻ cells (Figure 6A and 6B). However, frequency of CD103⁺IFN-
354 γ ⁺TNF⁺IL17A⁺-poly-functional and CD103⁻IFN- γ ⁻TNF⁺IL17A⁺-bi-functional airway
355 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells was higher in HIV-infected adults than HIV-
356 uninfected controls (Figure 6A and 6B). These results show that HIV infection,
357 minimally but differentially, impacts cytokine-functional profile of airway
358 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cell subsets.

359

360

361 **Discussion**

362 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells are part of the innate-like T cell family with
363 important functional relevance in defence against a diverse repertoire of pathogens.
364 There is limited data on the phenotypic and functional characteristics of human
365 airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells and how HIV impacts these cells in
366 asymptomatic individuals from high respiratory disease-burdened settings. This
367 study sheds new light on the functional capacity of human airway
368 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells, their compartmentalised nature, and demonstrates
369 selective depletion of CD103-expressing airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells in
370 untreated HIV-infected African adults, and reconstitution of airway
371 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells one year following ART initiation.

372

373 Consistent with observations that CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells possess different
374 functional characteristics related to their site of origin^{12, 13, 39}, we show that airway
375 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells are phenotypically and functionally different from
376 those in systemic circulation. Specifically, the majority of the airway
377 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells express mucosal retention receptor CD103, and
378 are more poly-functional than those from blood. Furthermore, CD103-expressing
379 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells exhibited propensity for IL-17A production. This is
380 constituent with recent observations from the oral mucosa, showing MAIT cells that
381 exhibit a tissue-resident-activated profile biased toward IL-17 production⁴⁴. IL-17
382 plays an important role in mucosal defense as it acts as a bridge between innate and
383 adaptive immunity⁴⁵⁻⁴⁷ and also induces production of antimicrobial peptides⁴⁸. Due
384 to the innate-like function of airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells, production of
385 IL-17A and expression of CD103 likely confers these cells readiness and immediate
386 availability to respond quickly to pathogens at a major portal of entry. This is
387 evidenced by observations in animal models that show poor early control of
388 respiratory infections in CD161⁺⁺TCRv α 7.2⁺ T cell-deficient animals compared to
389 wild type controls^{32, 33}.

390

391 Certainly, disruption of airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cell homeostasis could
392 contribute to increased susceptibility to respiratory infections. Consistent with data
393 from non-human primates⁴⁹, we show a depletion in airway
394 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells in untreated HIV-infected adults. Specifically, we

395 show that CD103-expressing airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells are selectively
396 depleted in untreated HIV-infected adults. We also observed an inverse correlation
397 between HIV plasma viral load and frequency of airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T
398 cells, supporting a direct or indirect role of HIV in depletion of these cells. CD103 is
399 required for retention of cells in tissues as it binds to epithelial cell-expressed E-
400 cadherin^{41, 42}. CD4⁺ T cells are important for the formation of functional
401 CD103⁺CD8⁺ T cells, and we have shown in this study that the frequency of CD103-
402 expressing airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells was positively correlated with
403 the frequency of airway CD4⁺ T cells. It has been shown that absence of CD4⁺ T
404 cells leads to reduced expression of CD103 on CD8⁺ T cells and subsequent
405 mislocalisation of these cells away from airway epithelia⁵⁰. Downregulation of
406 CD103 could potentially result in egress of CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells from the
407 airway lumen. It is also plausible that HIV-induced immune activation could lead
408 activation-induced cell death (AICD)⁵¹, immune exhaustion³¹ or to upregulation of
409 intergrins in the lung tissue, resulting in impaired trafficking of CD8⁺ MAIT cells from
410 the tissue into the airway lumen. This could result in poor replenishment of CD103-
411 expressing airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in the airway lumen.

412
413 Consistent with a potential direct or indirect role of HIV on alteration of airway
414 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cell homeostasis, suppressive ART was associated with
415 a reconstitution of airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells. CD161⁺⁺TCRvα7.2⁺ T
416 cell reconstitution has also been observed in colonic tissue from HIV-infected
417 individuals on ART⁵². In contrast to peripheral blood, where CD161⁺⁺TCRvα⁺ T cell
418 are not reconstituted by ART^{36, 52}, both colon and respiratory mucosa have diverse
419 microbiota rich with potential CD161⁺⁺TCRvα7.2⁺ T cell stimulating commensal
420 microbes⁵³. Microbial exposure shapes and maintains the CD161⁺⁺TCRvα7.2⁺ T cell
421 repertoire²². Germ-free mice lack CD161⁺⁺TCRvα7.2⁺ T cell, but acquire them after
422 reconstitution with commensal bacterial strains^{20, 54}. HIV infection disrupts the lung
423 microbiota⁵⁵ and this could compromise homeostatic maintenance of airway
424 CD161⁺⁺TCRvα7.2⁺ T cells. ART-mediated suppression of viremia could lead to
425 changes in the respiratory microbiota that favor recovery of CD161⁺⁺TCRvα7.2⁺ T
426 cell populations in the mucosal compartments.

427
428 Interestingly, HIV was not associated with impairment of cytokine-secreting
429 functional potential in airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells. This is consistent with
430 data showing retention of IFN-γ and TNF-producing function in peripheral blood-
431 derived CD161⁺⁺TCRvα7.2⁺ T cells stimulated with purified MR1 ligand in untreated
432 HIV-infected individuals³⁷. However, it is inconsistent with results obtained following
433 bacterial (*E. coli*) stimulation of peripheral blood-derived CD161⁺⁺TCRvα7.2⁺ T cells,
434 which showed lower levels of IFN-γ, TNF and IL-17 in untreated HIV-infected
435 individuals compared to healthy controls³⁸. It is therefore, plausible, that the
436 overpowering nature of PMA/Ionomycin stimulation could mask the small differences
437 in function between airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells from HIV-infected adults
438 and HIV-uninfected controls. On the other hand, PMA/Ionomycin stimulation brings
439 out the full cytokine-secreting functional potential of the airway
440 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells and by-passes the need for functional antigen-
441 presentation, which could potentially skew results in HIV-infected adults.

442

443 While our study provides useful insights into the phenotype and function of airway
444 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells, we acknowledge some limitations. First, we did not
445 use MR1 tetramers or other surface markers (such as CD26) to identify MAIT cells.
446 However, we have used CD161 and TCRvα7.2, classical MAIT cell markers used by
447 most studies in literature, as well as provided a representative flow cytometry plot
448 showing that over 70% of the CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells stain positive for
449 MR1-5-OP-RU Tetramer (Supplementary Figure 2). Second, we were only able to
450 perform serial bronchoscopy in a subset of individuals due to challenges associated
451 with serial research bronchoscopy. However, the data from the small subset of
452 participants was consistent with the earlier observations that showed an inverse
453 correlation between HIV plasma viral load and frequency of airway
454 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells. Third, we were not able to further characterize the
455 airway DN CD161⁺⁺TCRvα7.2⁺ T cells due to the limitation in event numbers.
456 However, in a subset, we were able to show that HIV infection did not impact this
457 airway DN CD161⁺⁺TCRvα7.2⁺ T cell population (Supplementary Figure 3).

458
459 In conclusion, we have shown that CD103-expressing airway
460 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells are functionally distinct from those in systemic
461 circulation, and are preferentially depleted during untreated asymptomatic HIV
462 infection. Disruption of airway CD8⁺CD161⁺⁺TCRvα7.2⁺ T cell homeostasis likely
463 creates a conducive environment for susceptible respiratory pathogens, and could
464 partly contribute to the increased propensity for LRTIs in HIV-infected adults.

466 **Acknowledgements**

467 The authors thank all study participants, staff of the Clinical Investigation Unit, MLW
468 and QECH for their support and co-operation during the study. The MR1-5-OP-RU
469 tetramer and MR1 6FP control were obtained from the NIH Tetramer Core Facility at
470 Emory University.

471
472
473
474 *Potential conflicts of interest:* All authors - No reported conflicts.

475 476 477 478 **References**

- 479 1. Martinson NA, Hoffmann CJ, Chaisson RE. Epidemiology of tuberculosis and
480 HIV: recent advances in understanding and responses. *Proc Am Thorac Soc*
481 2011; **8**(3): 288-293.
- 482
483 2. Segal LN, Methe BA, Nolan A, Hoshino Y, Rom WN, Dawson R *et al.* HIV-1
484 and bacterial pneumonia in the era of antiretroviral therapy. *Proc Am Thorac*
485 *Soc* 2011; **8**(3): 282-287.
- 486 3. Murray JF. Pulmonary complications of HIV-1 infection among adults living in
487 Sub-Saharan Africa. *IntJTuberLung Dis* 2005; **9**(8): 826.

488

- 489 4. Benito N, Moreno A, Miro JM, Torres A. Pulmonary infections in HIV-infected
490 patients: an update in the 21st century. *Eur Respir J* 2012; **39**(3): 730-745.
- 491 5. Mwale A, Hummel A, Mvaya L, Kamng'ona R, Chimbayo E, Phiri J *et al.* B
492 cell, CD8 (+) T cell and gamma delta T cell lymphocytic alveolitis alters
493 alveolar immune cell homeostasis in HIV-infected Malawian adults. *Wellcome*
494 *Open Res* 2017; **2**: 105.
- 495 6. Jambo KC, Banda DH, Afran L, Kankwatira AM, Malamba RD, Allain TJ *et al.*
496 Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit
497 impaired lung CD4(+) T-cell responses to mycobacteria. *Am J Respir Crit*
498 *Care Med* 2014; **190**(8): 938-947.
- 499 7. Jambo KC, Sepako E, Fullerton DG, Mzinza D, Glennie S, Wright AK *et al.*
500 Bronchoalveolar CD4+ T cell responses to respiratory antigens are impaired
501 in HIV-infected adults. *Thorax* 2011; **66**(5): 375-382.
- 502 8. Jambo KC, Banda DH, Kankwatira AM, Sukumar N, Allain TJ, Heyderman RS
503 *et al.* Small alveolar macrophages are infected preferentially by HIV and
504 exhibit impaired phagocytic function. *Mucosal Immunol* 2014.
- 505 9. Van Dyken SJ, Nussbaum JC, Lee J, Molofsky AB, Liang HE, Pollack JL *et al.*
506 A tissue checkpoint regulates type 2 immunity. *Nat Immunol* 2016; **17**(12):
507 1381-1387.
- 508 10. Meierovics A, Yankelevich WJ, Cowley SC. MAIT cells are critical for optimal
509 mucosal immune responses during in vivo pulmonary bacterial infection. *Proc*
510 *Natl Acad Sci U S A* 2013; **110**(33): E3119-3128.
- 511 11. Billerbeck E, Kang YH, Walker L, Lockstone H, Grafmueller S, Fleming V *et al.*
512 Analysis of CD161 expression on human CD8+ T cells defines a distinct
513 functional subset with tissue-homing properties. *Proc Natl Acad Sci U S A*
514 2010; **107**(7): 3006-3011.
- 515 12. Gibbs A, Leeansyah E, Introini A, Paquin-Proulx D, Hasselrot K, Andersson E
516 *et al.* MAIT cells reside in the female genital mucosa and are biased towards
517 IL-17 and IL-22 production in response to bacterial stimulation. *Mucosal*
518 *Immunol* 2017; **10**(1): 35-45.
- 519 13. Jiang J, Chen X, An H, Yang B, Zhang F, Cheng X. Enhanced immune
520 response of MAIT cells in tuberculous pleural effusions depends on cytokine
521 signaling. *Sci Rep* 2016; **6**: 32320.
- 522 14. Sharma PK, Wong EB, Napier RJ, Bishai WR, Ndung'u T, Kasproicz VO *et al.*
523 High expression of CD26 accurately identifies human bacteria-reactive
524 MR1-restricted MAIT cells. *Immunology* 2015; **145**(3): 443-453.
- 525 15. Chen Z, Wang H, D'Souza C, Sun S, Kostenko L, Eckle SB *et al.* Mucosal-
526 associated invariant T-cell activation and accumulation after in vivo infection
527 depends on microbial riboflavin synthesis and co-stimulatory signals. *Mucosal*
528 *Immunol* 2017; **10**(1): 58-68.
- 529

- 530 16. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J *et al.*
531 Human mucosal associated invariant T cells detect bacterially infected cells.
532 *PLoS Biol* 2010; **8**(6): e1000407.
- 533 17. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M *et al.*
534 Antimicrobial activity of mucosal-associated invariant T cells. *Nat Immunol*
535 2010; **11**(8): 701-708.
- 536 18. Dias J, Boulouis C, Gorin JB, van den Biggelaar R, Lal KG, Gibbs A *et al.* The
537 CD4(-)CD8(-) MAIT cell subpopulation is a functionally distinct subset
538 developmentally related to the main CD8(+) MAIT cell pool. *Proc Natl Acad*
539 *Sci U S A* 2018; **115**(49): E11513-E11522.
- 540 19. Yong YK, Tan HY, Saeidi A, Rosmawati M, Atiya N, Ansari AW *et al.*
541 Decrease of CD69 levels on TCR Valpha7.2(+)CD4(+) innate-like
542 lymphocytes is associated with impaired cytotoxic functions in chronic
543 hepatitis B virus-infected patients. *Innate Immun* 2017; **23**(5): 459-467.
- 544 20. Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C *et al.* Stepwise
545 development of MAIT cells in mouse and human. *PLoS Biol* 2009; **7**(3): e54.
- 546 21. Leeansyah E, Loh L, Nixon DF, Sandberg JK. Acquisition of innate-like
547 microbial reactivity in mucosal tissues during human fetal MAIT-cell
548 development. *Nat Commun* 2014; **5**: 3143.
- 549 22. Gold MC, Napier RJ, Lewinsohn DM. MR1-restricted mucosal associated
550 invariant T (MAIT) cells in the immune response to Mycobacterium
551 tuberculosis. *Immunol Rev* 2015; **264**(1): 154-166.
- 552 23. Ussher JE, Klenerman P, Willberg CB. Mucosal-associated invariant T-cells:
553 new players in anti-bacterial immunity. *Front Immunol* 2014; **5**: 450.
- 554 24. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity,
555 inflammation and tissue homeostasis at barrier surfaces by IL-22. *Nat*
556 *Immunol* 2011; **12**(5): 383-390.
- 557 25. Kim CJ, Nazli A, Rojas OL, Chege D, Alidina Z, Huibner S *et al.* A role for
558 mucosal IL-22 production and Th22 cells in HIV-associated mucosal
559 immunopathogenesis. *Mucosal Immunol* 2012; **5**(6): 670-680.
- 560 26. Kurioka A, van Wilgenburg B, Javan RR, Hoyle R, van Tonder AJ, Harrold CL
561 *et al.* Diverse Streptococcus pneumoniae Strains Drive a Mucosal-Associated
562 Invariant T-Cell Response Through Major Histocompatibility Complex class I-
563 Related Molecule-Dependent and Cytokine-Driven Pathways. *J Infect Dis*
564 2018; **217**(6): 988-999.
- 565 27. Kwon YS, Cho YN, Kim MJ, Jin HM, Jung HJ, Kang JH *et al.* Mucosal-
566 associated invariant T cells are numerically and functionally deficient in
567 patients with mycobacterial infection and reflect disease activity. *Tuberculosis*
568 (*Edinb*) 2015; **95**(3): 267-274.

569

- 570 28. Jiang J, Wang X, An H, Yang B, Cao Z, Liu Y *et al.* Mucosal-associated
571 invariant T-cell function is modulated by programmed death-1 signaling in
572 patients with active tuberculosis. *Am J Respir Crit Care Med* 2014; **190**(3):
573 329-339.
- 574 29. Barathan M, Mohamed R, Vadivelu J, Chang LY, Saeidi A, Yong YK *et al.*
575 Peripheral loss of CD8(+) CD161(++) TCRValpha7.2(+) mucosal-associated
576 invariant T cells in chronic hepatitis C virus-infected patients. *Eur J Clin Invest*
577 2016; **46**(2): 170-180.
- 578 30. Saeidi A, Tien Tien VL, Al-Batran R, Al-Darraji HA, Tan HY, Yong YK *et al.*
579 Attrition of TCR Valpha7.2+ CD161++ MAIT cells in HIV-tuberculosis co-
580 infection is associated with elevated levels of PD-1 expression. *PLoS One*
581 2015; **10**(4): e0124659.
- 582 31. Saeidi A, Ellegard R, Yong YK, Tan HY, Velu V, Ussher JE *et al.* Functional
583 role of mucosal-associated invariant T cells in HIV infection. *J Leukoc Biol*
584 2016; **100**(2): 305-314.
- 585 32. Sakala IG, Kjer-Nielsen L, Eickhoff CS, Wang X, Blazevic A, Liu L *et al.*
586 Functional Heterogeneity and Antimycobacterial Effects of Mouse Mucosal-
587 Associated Invariant T Cells Specific for Riboflavin Metabolites. *J Immunol*
588 2015; **195**(2): 587-601.
- 589 33. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH.
590 Polyclonal mucosa-associated invariant T cells have unique innate functions
591 in bacterial infection. *Infect Immun* 2012; **80**(9): 3256-3267.
- 592 34. Leeansyah E, Ganesh A, Quigley MF, Sonnerborg A, Andersson J, Hunt PW
593 *et al.* Activation, exhaustion, and persistent decline of the antimicrobial MR1-
594 restricted MAIT-cell population in chronic HIV-1 infection. *Blood* 2013; **121**(7):
595 1124-1135.
- 596 35. Wong EB, Akilimali NA, Govender P, Sullivan ZA, Cosgrove C, Pillay M *et al.*
597 Low levels of peripheral CD161++CD8+ mucosal associated invariant T
598 (MAIT) cells are found in HIV and HIV/TB co-infection. *PLoS One* 2013; **8**(12):
599 e83474.
- 600 36. Cosgrove C, Ussher JE, Rauch A, Gartner K, Kurioka A, Huhn MH *et al.* Early
601 and nonreversible decrease of CD161++ /MAIT cells in HIV infection. *Blood*
602 2013; **121**(6): 951-961.
- 603 37. Fernandez CS, Amarasena T, Kelleher AD, Rossjohn J, McCluskey J,
604 Godfrey DI *et al.* MAIT cells are depleted early but retain functional cytokine
605 expression in HIV infection. *Immunol Cell Biol* 2015; **93**(2): 177-188.
- 606 38. Leeansyah E, Svard J, Dias J, Buggert M, Nystrom J, Quigley MF *et al.*
607 Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and
608 Defective in HIV-1 Infection. *PLoS Pathog* 2015; **11**(8): e1005072.
- 609

- 610 39. Booth JS, Salerno-Goncalves R, Blanchard TG, Patil SA, Kader HA, Safta AM
611 *et al.* Mucosal-Associated Invariant T Cells in the Human Gastric Mucosa and
612 Blood: Role in Helicobacter pylori Infection. *Front Immunol* 2015; **6**: 466.
- 613 40. Cheuk S, Schlums H, Gallais Serezal I, Martini E, Chiang SC, Marquardt N *et al.*
614 CD49a Expression Defines Tissue-Resident CD8(+) T Cells Poised for
615 Cytotoxic Function in Human Skin. *Immunity* 2017; **46**(2): 287-300.
- 616 41. Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL *et al.*
617 Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin
618 and the alpha E beta 7 integrin. *Nature* 1994; **372**(6502): 190-193.
- 619 42. Topham DJ, Reilly EC. Tissue-Resident Memory CD8(+) T Cells: From
620 Phenotype to Function. *Front Immunol* 2018; **9**: 515.
- 621 43. Cummins NW, Badley AD. Mechanisms of HIV-associated lymphocyte
622 apoptosis: 2010. *Cell Death Dis* 2010; **1**: e99.
- 623 44. Sobkowiak MJ, Davanian H, Heymann R, Gibbs A, Emgard J, Dias J *et al.*
624 Tissue-resident MAIT cell populations in human oral mucosa exhibit an
625 activated profile and produce IL-17. *Eur J Immunol* 2019; **49**(1): 133-143.
- 626 45. Guglani L, Khader SA. Th17 cytokines in mucosal immunity and inflammation.
627 *Curr Opin HIV AIDS* 2010; **5**(2): 120-127.
- 628 46. Chen K, Eddens T, Trevejo-Nunez G, Way EE, Elsegeiny W, Ricks DM *et al.*
629 IL-17 Receptor Signaling in the Lung Epithelium Is Required for Mucosal
630 Chemokine Gradients and Pulmonary Host Defense against K. pneumoniae.
631 *Cell Host Microbe* 2016; **20**(5): 596-605.
- 632 47. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y *et al.*
633 Differential roles of interleukin-17A and -17F in host defense against
634 mucoepithelial bacterial infection and allergic responses. *Immunity* 2009;
635 **30**(1): 108-119.
- 636 48. Archer NK, Adappa ND, Palmer JN, Cohen NA, Harro JM, Lee SK *et al.*
637 Interleukin-17A (IL-17A) and IL-17F Are Critical for Antimicrobial Peptide
638 Production and Clearance of Staphylococcus aureus Nasal Colonization.
639 *Infect Immun* 2016; **84**(12): 3575-3583.
- 640 49. Vinton C, Wu F, Rossjohn J, Matsuda K, McCluskey J, Hirsch V *et al.*
641 Mucosa-Associated Invariant T Cells Are Systemically Depleted in Simian
642 Immunodeficiency Virus-Infected Rhesus Macaques. *J Virol* 2016; **90**(9):
643 4520-4529.
- 644 50. Laidlaw BJ, Zhang N, Marshall HD, Staron MM, Guan T, Hu Y *et al.* CD4+ T
645 cell help guides formation of CD103+ lung-resident memory CD8+ T cells
646 during influenza viral infection. *Immunity* 2014; **41**(4): 633-645.
- 647 51. Popescu I, Drummond MB, Gama L, Coon T, Merlo CA, Wise RA *et al.*
648 Activation-induced cell death drives profound lung CD4(+) T-cell depletion in
649 HIV-associated chronic obstructive pulmonary disease. *Am J Respir Crit Care*
650 *Med* 2014; **190**(7): 744-755.

- 651
652 52. Greathead L, Metcalf R, Gazzard B, Gotch F, Steel A, Kelleher P.
653 CD8+/CD161++ mucosal-associated invariant T-cell levels in the colon are
654 restored on long-term antiretroviral therapy and correlate with CD8+ T-cell
655 immune activation. *AIDS* 2014; **28**(11): 1690-1692.
- 656 53. Ringel Y, Maharshak N, Ringel-Kulka T, Wolber EA, Sartor RB, Carroll IM.
657 High throughput sequencing reveals distinct microbial populations within the
658 mucosal and luminal niches in healthy individuals. *Gut Microbes* 2015; **6**(3):
659 173-181.
- 660 54. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F *et al.*
661 Selection of evolutionarily conserved mucosal-associated invariant T cells by
662 MR1. *Nature* 2003; **422**(6928): 164-169.
- 663 55. Twigg HL, 3rd, Weinstock GM, Knox KS. Lung microbiome in human
664 immunodeficiency virus infection. *Transl Res* 2017; **179**: 97-107.

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

In review

697 **Figure legends**

698 **Figure 1. Identification of CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in airway lumen and**
699 **peripheral circulation.** BAL cells and PBMCs from HIV-uninfected adults were
700 stained with fluorochrome-conjugated antibodies against surface markers of interest.
701 **A)** Representative flow cytometry plots showing CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in
702 matched BAL and PBMC samples from a healthy HIV-uninfected adult. **B)**
703 Frequency of CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells cells in BAL compared to blood. **C)**
704 Memory phenotype of CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells cells in BAL compared to
705 blood. Data were analysed using Wilcoxon matched-pairs signed rank test (n=20).
706 BAL, bronchoalveolar lavage; PBMC, peripheral blood mononuclear cells
707

708 **Figure 2. Characterization of CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in airway lumen**
709 **and peripheral circulation.** BAL cells and PBMCs from HIV-uninfected adults were
710 stained with fluorochrome-conjugated antibodies against surface markers of interest.
711 **A)** Representative flow cytometry plots showing CD103-expression in CD8⁺ T cells in
712 matched BAL and PBMC samples from two healthy HIV-uninfected adults. **B)**
713 Proportion of CD103-expressing CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in BAL and
714 PBMCs. **C)** CD103 expression intensity in CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells
715 compared to classical CD8⁺ T cells from the airway lumen. Data were analysed
716 using Wilcoxon matched-pairs signed rank test (n=19). BAL, bronchoalveolar lavage;
717 PBMC, peripheral blood mononuclear cells
718

719 **Figure 3. Functional profile of CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in airway lumen**
720 **and peripheral circulation.** BAL cells and PBMCs from HIV-uninfected adults were
721 stimulated with PMA/Ionomycin for 6 hours and responses were measured by
722 intracellular cytokine staining for TNF, IFN-γ and IL-17A. The response was obtained
723 by gating on singlets, lymphocytes, viable (LIVE/ DEAD Aqua), CD3⁺ cells, CD8⁺
724 cells/ CD8⁺CD161⁺⁺ TCRvα7.2⁺ T cells and combination of three cytokines. **A)** *Each*
725 *pie chart (top)* represents the mean distribution across subjects of mono-functional,
726 bi-functional and poly-functional cytokine producing cells (color coded as shown)
727 within the total response in a particular CD161⁺⁺TCRvα7.2⁺ T cell population. *Bar*
728 *charts (bottom)* represent the mean and standard error of the mean (SEM) of the
729 contribution of the indicated subset (x-axis) towards the total response against the
730 indicated CD161⁺⁺TCRvα7.2⁺ T cell subsets (color coded as shown). Permutation
731 test was performed among the pie charts and Wilcoxon test was done among the bar
732 charts using SPICE software (*p<0.05, **p<0.01). **B)** Frequency of IL17A-producing
733 cells in the CD103⁺ or CD103⁻ CD8⁺ T cell/ CD8⁺CD161⁺⁺TCRvα7.2⁺ T cell
734 populations subtracting background responses obtained from the non-stimulated
735 controls. The horizontal bars represent median, interquartile range and
736 highest/lowest value. Data were analysed using Mann Whitney test (n=11). BAL,
737 bronchoalveolar lavage; IFN, interferon-gamma; TNF, tumor necrosis factor; IL17,
738 interleukin-17A
739

740 **Figure 4. Depletion of airway CD103⁺CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells in**
741 **untreated HIV-infected adults.** BAL cells from HIV-uninfected and HIV-infected
742 adults were stained with fluorochrome-conjugated antibodies against surface
743 markers of interest. **A)** Flow cytometry dot plots showing depletion of
744 CD8⁺CD161⁺⁺TCRvα7.2⁺ T cells. **B)** Frequency of airway CD8⁺CD161⁺⁺TCRvα7.2⁺
745 T cells in HIV-infected individuals compared to healthy controls (HIV-, n=39; HIV+,

746 n=41). **C)** Frequency of CD103[±] airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells in HIV-
747 infected individuals compared to healthy controls (HIV-, n=19; HIV+, n=21). **D)**
748 Frequency of total CD8⁺ T cells and CD4⁺ T cells in HIV-infected individuals
749 compared to healthy controls (HIV-, n=19; HIV+, n=21). **E)** Distribution of CD103[±]
750 airway CD161⁺⁺TCRv α 7.2⁺ T cells in HIV-infected individuals compared to healthy
751 controls (HIV-, n=19; HIV+, n=21). **F)** Association between frequency of airway
752 CD103⁺ CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells and proportion of airway CD4⁺ T cells
753 (n=40; HIV- n=19, HIV+ n=21). Data were analysed using Mann Whitney test and the
754 horizontal bars represent median, and interquartile range (**B, C, D**). Data were
755 analysed using Fisher's exact test (**E**). Data was analysed using Pearson correlation
756 test (**F**). BAL, bronchoalveolar lavage

757

758 **Figure 5. Depletion of airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells is inversely**
759 **correlated with HIV plasma viral load. A)** Association between plasma viral load
760 and frequency of airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells. Plasma viral load was log
761 transformed (n=25). **B)** Association between peripheral blood CD4 count and
762 frequency of airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells (n=25). **C)** Representative flow
763 cytometry plots from an HIV-infected adult before and one year post ART initiation.
764 **B)** Frequency of airway CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells in from HIV-uninfected
765 adults (before and one year post ART initiation) compared to healthy controls (HIV+
766 ART-/+, n=6). Data was analysed using Pearson correlation test (**A-B**). Data were
767 analysed using Wilcoxon matched-pairs signed rank test for paired comparisons (**C**).
768 ART, anti-retroviral therapy

769

770

771 **Figure 6. Function profile of CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cells in healthy HIV-**
772 **uninfected individuals compared to HIV-infected adults.** BAL cells were
773 stimulated with PMA/Ionomycin for 6 hours and responses were measured by
774 intracellular cytokine staining for IL-17A, IFN- γ and TNF. The phenotype of the
775 responding cells was obtained by gating on singlets, lymphocytes, viable (LIVE/
776 DEAD Aqua), CD3⁺ cells, CD8⁺ cells, IL-17A⁺, and then a combination of CD161 and
777 CD103. **A)** CD103⁺ and **B)** CD103⁻. Each pie chart (top) represents the mean
778 distribution across subjects of mono-functional, bi-functional and poly-functional
779 cytokine producing cells (color coded as shown) within the total response in a
780 particular CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cell subset. Bar charts (bottom) represent the
781 mean and standard error of the mean (SEM) of the contribution of the indicated
782 subset (x-axis) towards the total response against the indicated
783 CD8⁺CD161⁺⁺TCRv α 7.2⁺ T cell subsets (color coded as shown) (n=11). Permutation
784 test was performed among the pie charts and Wilcoxon test was done among the bar
785 charts using SPICE software (*p<0.05, **p<0.01). BAL, bronchoalveolar; IFN,
786 interferon-gamma; TNF, tumor necrosis factor; IL17, interleukin-17A

787

788

789

790

791

Table 1: Demographics of study participants

	HIV-uninfected controls (n=39)	HIV-infected adults (n=41)	p value
Age (years), Median (range)	32 (18-52)	32 (21-58)	0.4063*
Sex (M: F)	30:9	21:20	0.0398**
CD4 count (cells/ μ l), Median (IQR)	671 (523-815)	319 (213-471)	<0.0001*
Plasma viral load (log 10 Copies/mL), Median (range)	N/A	4.08 (2.2-5.8)	N/A

*Unpaired T test

**Fishers exact test

IQR, Interquartile range; ART, antiretroviral therapy; N/A, not applicable

In review

Figure 1.TIFF




Figure 2.TIFF




Figure 3.TIFF






Figure 4.TIFF




Figure 5.TIFF






Figure 6.TIFF

A.



B.

